Caribou Biosciences Inc
CRBUHealthcare|Biotechnology|USA
$1.93
-0.01 (-0.77%)
Tangible Book
$1.05
Clinical Trials (5)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05722418 CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma | Relapsed/Refractory Multiple Myeloma | P1 | Recruiting | 50 | Open-label | CB-011 |
| NCT04637763 CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) | Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma | P1 | Unknown | 72 | Open-label | Cyclophosphamide, Fludarabine |
| NCT06128044 CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | P1 | Terminated | 12 | Open-label | CB-012 |
| NCT06752876 CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP) | Systemic Lupus Erythematosus, Lupus | P1 | Withdrawn | — | Open-label | CB-010 |
| NCT05332054 Long-Term Follow-up Study | Lymphoma, Non-Hodgkin, Relapsed Non-Hodgkin Lymphoma | By Invite | 150 | — | Caribou-sponsored investigational therapy |